Halozyme Therapeutics, Inc. — Q3 2015 Form 10-Q
Reporting period: Three and nine months ended September 30, 2015. Financial statements are unaudited. Halozyme is a biotechnology company developing oncology therapies, led by PEGPH20, and licensing its Enhanze rHuPH20 technology to biopharma partners. Its marketed products include Hylenex; collaborators’ products generate royalties and supply revenue.
Financial performance
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Total revenue | $20.8m | $14.6m | $82.8m | $45.0m |
| Operating loss | $23.2m | $19.0m | $32.9m | $59.2m |
| Net loss | $24.5m | $20.3m | $36.5m | $63.1m |
| Net loss per share, diluted | $0.19 | $0.16 | $0.29 | $0.52 |
Revenue mix: Q3 product sales were $10.3m, royalties $8.3m, and collaborative-agreement revenue $2.2m. Nine-month amounts were $32.5m, $21.4m, and $28.9m, respectively. The nine-month collaborative revenue included a $23.0m AbbVie upfront license fee. Royalty growth primarily reflected Roche’s higher Herceptin SC sales.
Expenses and margins: Q3 operating expenses were $44.0m, including R&D of $27.6m and SG&A of $10.2m. Nine-month operating expenses were $115.7m, including R&D of $65.5m and SG&A of $29.4m. Q3 cost of product sales was $6.2m; nine-month cost was $20.8m. Product gross margin is not presented as a company-reported metric.
Cash flow and liquidity: For the first nine months, operating cash use was $21.9m, investing activities provided $20.6m, and financing activities provided $11.4m. Cash and cash equivalents rose to $71.5m from $61.4m at year-end 2014. Cash, cash equivalents and marketable securities totaled $123.7m at September 30. Current assets were $153.1m versus current liabilities of $44.9m.
Debt: Debt was approximately $49.8m, net of discount, with $15.7m classified current and $34.1m long term. The loan bears 7.55% interest, matures January 2018, and requires interest-only payments through January 2016, followed by monthly principal and interest. It is secured by substantially all company assets subject to exclusions; Halozyme reported covenant compliance.
Material changes versus comparable periods
- Nine-month revenue rose 84%, driven by royalties and the AbbVie upfront license recognition; Q3 revenue rose 42%, principally on royalties.
- Nine-month net loss narrowed by $26.6m, while Q3 net loss widened by $4.2m. Q3 R&D increased $7.7m year over year, mainly from PEGPH20 trial activity; nine-month PEGPH20 R&D increased $28.6m.
- Nine-month operating cash use fell by $24.7m, mainly because of the lower net loss, partly offset by increased inventory. The 2014 financing comparison included $107.7m of net proceeds from an equity offering; no comparable offering occurred in 2015.
- Inventory increased to $11.1m from $6.4m at December 31, 2014, primarily reflecting higher bulk rHuPH20 inventory. Total deferred revenue declined to $50.0m from $54.6m.
Outlook, commentary and risks
- Management expected existing cash and marketable securities to fund operations for at least 12 months and forecast 2015 net cash burn of approximately $20m–$30m. It anticipated higher R&D spending as PEGPH20 development advanced and moderate SG&A growth.
- Halozyme planned to initiate the Phase 3 PEGPH20 metastatic pancreatic cancer study by the end of Q1 2016, subject to companion-diagnostic requirements. It planned to complete Phase 2 Study 109-202 enrollment of 114 additional patients by year-end 2015 and report results in the second half of 2016.
- Study 109-202 had previously been placed on clinical hold over a possible thromboembolic-event imbalance. The revised protocol excludes higher-risk patients and requires anticoagulant prophylaxis; the study may be halted again if event rates or other safety concerns warrant. Interim high-HA subgroup results showed improved PFS and response rates, but these were interim findings, not definitive evidence of approval or commercial benefit.
- Key business risks include clinical efficacy and safety, regulatory approval and companion-diagnostic development, reliance on contract manufacturers and collaborators, uncertain partner-driven royalties and milestones, and ongoing cash needs. The company cautioned that financing may be required before it becomes cash-flow positive.
- One-time collaboration revenue was material to the nine-month comparison: the $23.0m AbbVie license fee was recognized upon granting the license. Other unusual commercial developments included Pfizer’s October 2015 Phase 1 dosing milestone for Rivipansel and Janssen’s November 2015 initiation of Phase 1b dosing with daratumumab.
- Halozyme reported no material legal proceeding and said disclosure controls were effective. Its November 2015 change-in-control agreement amendments provide specified severance and accelerated equity vesting for qualifying executives.
Important facts for investors to verify
- Whether PEGPH20’s Phase 2 efficacy and safety findings are confirmed in larger trials, and whether thromboembolic risks remain controlled.
- Timing and regulatory acceptability of the companion diagnostic and planned Phase 3 study.
- Roche, Baxalta and other partners’ product sales, commercialization progress, and resulting royalties and supply demand.
- Actual cash burn versus the $20m–$30m 2015 estimate, available liquidity, and funding needs relative to debt repayments beginning in 2016.
- Manufacturing capacity and supply reliability for rHuPH20 and PEGPH20, and any emerging antibody or other safety concerns.